Trials / Recruiting

RecruitingNCT04273061

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention

Status: Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 200 (estimated)

Sponsor: British Columbia Cancer Agency · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.

Conditions

Interventions

Type	Name	Description
DRUG	Atezolizumab	1200 mg by intravenous infusion every 3 weeks as tolerated

Timeline

Start date: 2020-06-17
Primary completion: 2027-10-01
Completion: 2027-10-01
First posted: 2020-02-17
Last updated: 2025-09-22

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04273061. Inclusion in this directory is not an endorsement.